Clinical Characteristics of Coronavirus Disease 2019 in Dr. Agoesdjam Regional Public Hospital, Ketapang, West Kalimantan, Indonesia

Herick Alvenus Willim, Cristianto Cristianto, Yohana Roy Ito Br Sihombing, Eva Lydia Munthe, Widi Mujono, Enny Enny


Background: Coronavirus disease 2019 (COVID-19) is a new pandemic caused by SARS-CoV-2 infection. COVID-19 has spread to almost all countries with increasing cases, including Indonesia. Data on the clinical characteristics of COVID-19 in Indonesia is still limited. This study aimed to determine the clinical characteristics of COVID-19.

Subjects and Method: This study was a descriptive study with a retrospective design conducted in Dr. Agoesdjam Regional Public Hospital. The data were obtained from the medical records of all patients with confirmed COVID-19 from April 1 to July 31, 2020. There were 50 patients as the sample of the study. The data collected were demographics, expo­sure history, smoking status, comorbidities, clinical symptoms, outcomes, drug therapy, laboratory, chest X-ray, and electrocardio­graphy (ECG). This study used descriptive statistics.

Results: The patients on average aged 34.8 years (Mean= 34.8; SD= 14.0). Patients were dominated by the 30-39 years age group (28%) and men (56%). More than a third of patients (36%) were health workers. Most of the cases were local transmission (78%). Almost half of the patients (48%) were smokers. The most common comorbid was hypertension (12%). The dominant clinical symptoms were cough (34%), dyspnea (14%), and fever (10%). More than half of the patients (58%) were asymp­tomatic. The mortality rate was 2%. All patients received supportive therapy. Azithromycin was the most potential drug given (30%). Abnormal laboratory findings included leukocytosis (18%), neutrophilia (20%), lym­phopenia (28%), elevated erythrocyte sedi­mentation rate (32%), alanine aminotrans­ferase (36%), and aspartate aminotransferase (18%). Abnormal chest X-ray was found in 10% of patients. Among the 22 patients who were examined on the ECG, the abnormal figures were found in 40.9% of patients with non-specific findings.

Conclusion: The COVID-19 patients in this study are dominated by young adults and men. Asymptomatic and mild symptoms are more common. The symptoms that are often com­plained of are coughing, dyspnea, and fever. The common laboratory abnormalities were leucocytosis, neutrophilia, lymphopenia, elevated erythrocyte sedimentation rate, and elevated liver enzymes. The most common chest X-ray abnormality is consolidation. During the COVID-19 pandemic, prevention and control are the main priorities. In addition, the level of public awareness must be raised.

Keywords: COVID-19, SARS-CoV-2, clinical symptoms, electrocardiography

Correspondence: Herick Alvenus Willim. Dr. Agoesdjam Regio­nal Public Hospital, Ketapang Regency, West Kalimantan. Email: herick_alvenus@­yahoo.­ Mobile: +6282252188675.

Journal of Epidemiology and Public Health (2020), 05(03): 293-308


Full Text:



Akcay S, Ozlu T, Yilmaz A (2020). Radio-logical approaches to COVID-19 pneumonia. Turk J Med Sci, 50(3): 604–610. doi: 10.3906/sag-2004-160.

Alqahtani SA, Schattenberg JM (2020). Liver injury in COVID-19: the current evidence. United European Gastro-enterol J, 8(5): 509–519. doi: 10.1177-/2050640620924157.

Amaratunga EA, Corwin DS, Moran L, Sny-der R (2020). Bradycardia in patients with COVID-19: a calm before the storm? Cureus, 12(6): e8599. doi: 10.-7759/cureus.8599.

Angeli F, Spanevello A, Ponti RD, Visca D, Marazzato J, Palmiotto G, Feci D, et al. (2020). Electrocardiographic features of patients with COVID-19 pneumonia. Eur J Intern Med, 78: 101–106. doi: 10.1016/j.ejim.2020.0-6.015.

Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, et al. (2020) Treatment with hydroxy-chloroquine, azithromycin, and com-bination in patients hospitalized with COVID-19. Int J Infect Dis, 97: 396–403. doi: 10.1016/j.ijid.2020.06.099.

Bwire GM (2020). Coronavirus: why men are more vulnerable to Covid-19 than women? SN Compr Clin Med. doi: 10.1007/s42399-020-00341-w.

Cai G, Bosse Y, Xiao F, Kheradmand F, Amos CI (2020). Tobacco smoking increases the lung gene expression of ACE2, the receptor of SARS-CoV-2. Am J Respir Crit Care Med, 201(12): 1557–1559. doi: 10.1164/rccm.2020-03-0693LE.

Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, Li Z, et al. (2020). COVID-19: abnor-mal liver function tests.J Hepatol, 73(3): 566–574. doi: 10.1016/j.jhep.2020.04.006.

Cao Z, Li T, Liang L, Wang H, Wei F, Meng S, Cai M, et al. (2020). Clinical characteristics of coronavirus disease 2019 patients in Beijing, China.PLoS One, 15(6): e0234764. doi: 10.1371/journal.pone.0234764.

Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, Knotts R, et al. (2020). QT interval prolongation and torsade de pointes in patients with COVID-19 treated with hydroxychloroquine/azithromycin. Heart Rhythm, 17(9):1425-1433. doi: 10.1016/j.hrthm.2020.05.014.

Cleverley J, Piper J, Jones MM (2020). The role of chest radiography in confirming covid-19 pneumonia. BMJ, 370: m2426. doi: 10.1136/bmj.m2426.

Colaneri M, Sacchi P, Zuccaro V, Biscarini S, Sachs M, Roda S, Pieri TC, et al. (2020). Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020.Euro Surveill, 25(16): 2000460. doi: 10.2807/15607917.ES.2020.25.16.2000460.

Cozzi D, Albanesi M, Cavigli E, Moroni C, Bindi A, Luvara S, Lucarini S, et al. (2020). Chest x-ray in new corona-virus disease 2019 (COVID-19) infec-tion: findings and correlation with clinical outcome. Radiol Med. doi: 10.1007/s11547-020-01232-9.

Dhand R, Li J (2020). Coughs and sneezes: their role in transmission of respira-tory viral infections, including SARS-CoV-2. Am J Respir Crit Care Med, 202(5): 651-659. doi: 10.1164/rccm.202004-1263pp.

Dinas Kesehatan Kalimantan Barat (2020). Dashboard COVID-19 Kalbar. Available at: (Accessed 3 September 2020).

Elezkurtaj S, Greuel S, Ihlow J, Michaelis E, Bischoff P, Kunze CA, Sinn VB, et al. (2020). Causes of death and comorbidities in patients with COVID-19. MedRxiv Preprint. doi: 10.1101/20-

Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-ran-domized clinical trial. Int J Anti-microb Agents, 56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, Liu L, et al. (2020). Clinical charac-teristics of coronavirus disease 2019 in China. N Engl J Med, 382:1708-1720. doi: 10.1056/NEJMoa2002032.

Hafiz M, Icksan AG, Harlivasari AD, Aulia R, Susanti F, Eldinia L (2020). Clinical, radiological features and out-come of COVID-19 patients in a secondary hospital in Jakarta, Indonesia. J Infect Dev Ctries, 14(7):750–757. doi: 10.3855/jidc.12911.

Hu H, Ma F, Wei X, Fang Y (2020). Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J: eha-a190. doi: 10.1093/eurheartj/ehaa190.

Hua J, Shaw R (2020). Corona virus (COVID-19) “infodemic” and emer-ging issues through a data lens: the case of China.Int J Environ Res Public Health, 17(7):2309. doi: 10.3390/ijerph17072309.

Huang G, Kovalic AJ, Graber CJ (2020). Prognostic value of leukocytosis and lymphopenia for coronavirus disease severity. Emerg Infect Dis, 26(8): 1839–1841. doi: 10.3201/eid2608.20-1160.

Itodo GE, Enitan SS, Oyekale AO, Agunsoye CJ, Asukwo UF, Enitan CB (2020). COVID-19 among healthcare workers: risk of exposure, impacts and biosafety measures – a review.IJHSE, 6(4):534–548.

Jajodia A, Ebner L, Heidinger B, Chatur vedi A, Prosch H (2020). Imaging in corona virus disease 2019 (COVID-19) a scoping review.Eur J Radiol Open, 7: 100237. doi: 10.1016/j.ejro.2020.100237.

Jin Y, Yang H, Ji W, Wu W, Chen S, Zhang W, Duan G (2020). Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses, 12(4):372. doi: 10.3390/v12040372.

Karyono DR, Wicaksana AL (2020). Cur-rent prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. JCOEMPH, 3(2): 77-84. doi: 10.22146/jcoemph.57325.

Kho J, Ioannou A, Abbeele KVD, Mandal AKJ, Missouris CG (2020). Pulmonary embolism in COVID-19: clinical characteristics and cardiac implications. Am J Emerg Med. doi: 10.1016-/j.ajem.2020.07.054.

Liao J, Fan S, Chen J, Wu J, Xu S, Guo Y, Li C, et al. (2020). Epidemiological and clinical characteristics of COVID-19 in adolescents and young adults. The Innovation, 1(1): 100001. doi: 10.1016/j.xinn.2020.04.001.

Lippi G, Mattiuzzi, C (2020). Hemoglobin value may be decreased in patients with severe coronavirus disease 2019. Hematol Transfus Cell Ther, 42(2): 116-117. doi: 10.1016/j.htct.2020.03.-001.

Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, et al. (2020). Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.J Transl Med, 18(1): 206. doi: 10.1186/s12967-020-02374-0.

Liu Y, Bi L, Chen Y, Wang Y, Fleming J, Yu Y, Gu Y, et al. (2020). Active or latent tuberculosis increases susceptibility to COVID-19 and disease severity. Med-Rxiv preprint. doi: 10.1101/2020.03.-10.20033795.

Mccullough SA, Goyal P, Krishnan U, Choi JJ, Safford MM, Okin PM (2020) Electrocardiographic findings in coronavirus disease-19: insights on mortality and underlying myocardial processes. J Card Fail, 26(7): 626-632. doi: 10.1016/j.cardfail.2020.06.005.

Merino JL, Martinez-Cossiani M, Iniesta A, Escobar C, Rey JR, Castrejon Castrejon S (2020). COVID-19 and QT interval prolongation: more than just drug toxicity? Europace, euaa145. doi: 10.1093/europace/euaa145.

Pinto BGG, Oliveira AER, Singh Y, Jimenez L, Goncalves ANA, Ogava RLT, et al. (2020). ACE2 expression is increased in the lungs of patients with comorbidities associated with severe CO-VID-19. J Infect Dis, 222(4): 556-563. doi: 10.1093/infdis/jiaa332.

Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, Villamiraz-Pena R, Holguin-Rivera Y, Escalera-Antezana JP, Alvarado-Arnez LE, et al. (2020). Clinical, laboratory and ima-ging features of COVID-19: a syste-matic review and meta-analysis.

Travel Med Infect Dis, 34: 101623. doi: 10.1016/j.tmaid.2020.101623.

Rosa SGV, Santos WC (2020). Clinical trials on drug repositioning for CO-VID-19 treatment.Rev Panam Salud Publica, 44:e40. doi: 10.26633/RPSP-.2020.40.

Sarkodie BD, Osei-Poku K, Brakohiapa E (2020). Diagnosing COVID-19 from chest x-ray in resource limited envi-ronment-case Report. Med Case Rep, 6(1): 135. doi: 10.36648/2471-8041.-6.2.135.

Sia CH, Ngiam JN, Chew N, Beh DLL, Poh LK (2020). Educational case series of electrocardiographs during the COVID-19 pandemic and the implications for therapy.Singapore Med J, 61(8): 406–412. doi: 10.11622/smedj.2020087.

Singhal T (2020). A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr, 87(4): 281-286. doi: 10.1007-/s12098-020-03263-6.

Sultana J, Cutroneo PM, Crisafulli S, Puglisi G, Caramori G, Trifiro G (2020). Azithromycin in COVID-19 patients: pharmacological mechanism, clinical evidence and prescribing guidelines. Drug Saf. doi: 10.1007/s40264-020-00976-7.

Violetis OA, Chasouraki AM, Giannou AM, Baraboutis IG (2020). COVID-19 infection and haematological involvement: a review of epidemiology, pathophysiology and prognosis of full blood count findings.SN Compr Clin Med. doi: 10.1007/s42399-020-003-80-3.

World Health Organization (2020). WHO Coronavirus Disease (COVID-19) Dashboard. Available at: (Accessed 3 September 2020).

Wong HYF, Lam HYS, Fong AHT, Leung ST, Chin TWY, Lo CSY, Lui MMS, et al. (2020). Frequency and distribu-tion of chest radiographic findings in patients positive for COVID-19. Radiology, 296(2): E72–E78. doi: 10.1148/radiol.2020201160.

Wu R, Wang L, Kuo HCD, Shannar A, Peter R, Chou PJ, Li S, et al. (2020). An update on current therapeutic drugs treating COVID-19. Curr Pharmacol Rep. doi: 10.1007/s40495-020-002-16-7.

Xu B, Xing Y, Peng J, Zheng Z, Tang W, Sun Y, Xu C, et al. (2020). Chest CT for detecting COVID-19: a systematic review and meta-analysis of diagnostic accuracy. Eur Radiol. doi: 10.21203/rs.3.rs20481/v1.

Yavuz SS, Unal S (2020). Antiviral treatment of COVID-19. Turk J Med Sci, 50(3): 611–619. doi: 10.3906/sag20-04-145.

Zeng F, Huang Y, Guo Y, Yin M, Chen X, Xiao L, Deng G (2020). Association of inflammatory markers with the severity of COVID-19: A meta-analysis.Int J Infect Dis, 96: 467-474. doi: 10.10-16/j.ijid.2020.05.055.

Zhao H, Lu X, Deng Y, Tang Y, Lu J (2020). COVID-19: asymptomatic carrier transmission is an underestimated problem. Epidemiol Infect, 148: e116. doi: 10.1017/S0950268820001235.

Zheng J (2020). SARS-CoV-2: an emerging coronavirus that causes a global threat. Int J Biol Sci, 16(10):1678-1685. doi: 10.7150/ijbs.45053.

Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X,et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019.N Engl J Med, 382(8): 727-733. doi: 10.1056/NEJ-Moa2001017.


  • There are currently no refbacks.